| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
Immunohistochemical double staining with antibodies for HLA-DR/CD68 (markers for M1-tumour-associated macrophage [M1-TAM]) or CD163/CD68 (M2-TAM) was performed to investigate the significance of TAMs in diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). In DLBCL, a higher number of M2-TAM was a significant factor for poor prognosis. The overall survival rate of the patients with DLBCL-IF, DLBCL showing an interfollicular pattern of proliferation preserving lymphoid follicles, was significantly better than those withDLBCL control group. All DLBCL-IF patients with a low M2-TAM count were alive at the end of observation. In HL, a higher number of M2-TAM was significantly correlated with shorter overall survival. When confined to mixed cellularity subtype of HL, a higher number of M1-TAM was significantly correlated with favorable prognosis.
|
